NuvalentNUVL
About: Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Employees: 127
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
74% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 27
42% more capital invested
Capital invested by funds: $5.04B [Q2] → $7.15B (+$2.11B) [Q3]
29% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 55
22% more funds holding in top 10
Funds holding in top 10: 9 [Q2] → 11 (+2) [Q3]
12% more funds holding
Funds holding: 172 [Q2] → 192 (+20) [Q3]
3.78% less ownership
Funds ownership: 112.34% [Q2] → 108.56% (-3.78%) [Q3]
30% less call options, than puts
Call options by funds: $46.7M | Put options by funds: $66.5M
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
BMO Capital Etzer Darout 45% 1-year accuracy 10 / 22 met price target | 42%upside $134 | Outperform Maintained | 13 Nov 2024 |
UBS David Dai 0% 1-year accuracy 0 / 9 met price target | 6%upside $100 | Neutral Initiated | 24 Oct 2024 |
JP Morgan Anupam Rama 47% 1-year accuracy 24 / 51 met price target | 32%upside $125 | Overweight Maintained | 4 Oct 2024 |
Guggenheim Kelsey Goodwin 33% 1-year accuracy 1 / 3 met price target | 11%upside $105 | Buy Maintained | 16 Sept 2024 |
Wedbush David Nierengarten 43% 1-year accuracy 23 / 54 met price target | 21%upside $115 | Outperform Maintained | 16 Sept 2024 |